Across TCGA pan-cancer cohorts, PELI1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PELI1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PELI1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PELI1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD and UCEC are the cancer types where PELI1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.001	33	view →
UCEC	DFS	Median	All	0.955	0.620	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PELI1 tumor-vs-normal RNA expression · all PELI1 data types